Waters Corporation (BMV:WAT)
Mexico
· Delayed Price · Currency is MXN | Market Cap | 511.50B |
| Revenue (ttm) | 56.99B |
| Net Income (ttm) | 11.57B |
| Shares Out | n/a |
| EPS (ttm) | 193.71 |
| PE Ratio | 44.21 |
| Forward PE | 21.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 357 |
| Open | 5,221.26 |
| Previous Close | 5,690.41 |
| Day's Range | 5,221.26 - 5,221.26 |
| 52-Week Range | 5,077.95 - 7,513.00 |
| Beta | n/a |
| RSI | 45.84 |
| Earnings Date | May 5, 2026 |
About Waters
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, p... [Read more]
Financial Performance
In 2025, Waters's revenue was $3.17 billion, an increase of 6.99% compared to the previous year's $2.96 billion. Earnings were $642.63 million, an increase of 0.75%.
Financial numbers in USDNews
Waters Corporation Schedules First Quarter 2026 Earnings Conference Call
MILFORD, Mass., April 20, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2026 financial results conference call on Tuesday, May 5, 2026 at 8:30 a.m.
Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules
Delivers up to 4x faster chromatographic run times to accelerate decisions across discovery, development, and quality workflows.1,3 Achieves 10x improvement in absolute molar mass and extended sizing,...
Waters Stock Shoots Higher As FDA Clears At-Home Cervical Cancer Screening Kit
Waters Corporation (NYSE:WAT) shares are up on Wednesday as the company announced FDA clearance for its Onclarity HPV Self-Collection Kit, a significant step in expanding access to cervical cancer scr...
Waters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay
FDA-approved BD Onclarity™ HPV Assay is the most comprehensive screening tool for HPV in the U.S.1,4 with extended genotyping and end-to-end automated lab workflows. At-home self-collection reduces si...
Waters Prices Offering of Senior Notes
MILFORD, Mass., March 18, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) (the "Company" or "Waters") today announced that it has priced an offering (the "Offering") of $3.5 billion aggregate prin...
Waters Flagship ARES‑G3 Rheometer Sets New Benchmark for Data Quality at Breakthrough Speed
News Summary: Reduces standard testing times by 80%.1 Delivers an industry-leading 25,000 data points per second, detecting transient material behaviors previously invisible to measurement. 2 Operates...
Waters Transcript: TD Cowen 46th Annual Health Care Conference
Integration of the BD acquisition is progressing, with a focus on operational precision and cross-team learning. Financial guidance is conservative due to China headwinds, but margin and EPS targets are maintained. Core business growth is supported by strong recurring revenues and new product innovation.
Waters Corporation to Present at the TD Cowen Health Care Conference
MILFORD, Mass., Feb. 23, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.
Waters Introduces Next-Generation Microflow LC Columns with MaxPeak Premier Technology, Delivering Higher Sensitivity with Lower Sample and Solvent Usage
Headlines: Delivers up to 2× higher sensitivity than stainless steel microflow columns, lowering detection and quantitation limits across high-throughput bioseparations, DMPK, and 'omics applications....
Why Is Waters Stock Sinking Monday?
Waters Corporation (NYSE: WAT) stock is trading lower on Monday after the company released fourth-quarter 2025 financial results and issued fiscal 2026 guidance.
BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation
FRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) today announced the successful completion of the previously announced spin-off of BD's Biosciences & D...
Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses
Announces appointment of Claire M. Fraser, Ph.D.
Waters Earnings Call Transcript: Q4 2025
Delivered strong Q4 and full-year growth, completed BD acquisition, and set 2026 guidance for 5.3% blended revenue growth and 8.9–10.4% adjusted EPS growth. Integration and synergy initiatives are underway, with robust momentum in pharma, chemistry, and recurring revenue.
Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2025 Financial Results
Highlights Fourth Quarter 2025 Sales of $932 million landed at the high-end of reported sales growth guidance range; grew 7% as reported and 6% in constant currency Growth led by high single-digit con...
BD Announces Record Date for the Spin-Off of its Biosciences & Diagnostic Solutions Business
Distribution date and closing date for spin-off and merger with Waters Corporation set for February 9, 2026 FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE...
Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business
Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday, February 9th, 2026 at 8:30am ET in conjunction with the expected close of the transaction MILFORD, Mass., Ja...
Waters Corporation Schedules Fourth Quarter 2025 Earnings Conference Call
MILFORD, Mass., Jan. 20, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q4 2025 financial results conference call on Thursday, February 12th, 2026 at 8:00 a.m.
Waters Transcript: 44th Annual J.P. Morgan Healthcare Conference
A five-year transformation drove commercial and innovation gains, expanding into high-growth adjacencies and culminating in the acquisition of BD's Bioscience and Diagnostics business. The integration is expected to deliver significant cost and revenue synergies, with a strong financial outlook and continued leadership in innovation and growth.
Waters Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026
MILFORD, Mass., Dec. 23, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan ...
Waters Transcript: Jefferies London Healthcare Conference 2025
Instrument replacement cycles and innovation in bioseparations, informatics, and diagnostics are driving strong growth, with new products and software models expanding market share. Integration of BD is on track, and forward-looking initiatives are expected to sustain higher growth rates.
Waters Corporation to Present at the Jefferies Global Healthcare Conference in London
MILFORD, Mass. , Nov. 11, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.
Waters Boosts Lab Productivity and Sample Throughput with Launch of its Charged Aerosol Detector Designed for Empower Software
Drives efficiency and reliability in Quality Control and Development environments, integrating seamlessly with world-class Empower™ Chromatography Data System (CDS). Mitigates CDS communication errors...
Waters Earnings Call Transcript: Q3 2025
Q3 sales and earnings exceeded guidance, with 8% revenue growth and 16% adjusted EPS growth. Pharma and Chemistry segments led performance, and the outlook for 2025 and 2026 remains strong, supported by innovation, new product launches, and the pending BD combination.
Waters Corp raises annual profit forecast on stronger lab equipment demand
Lab equipment maker Waters Corp raised its annual profit forecast on Tuesday, after beating third-quarter profit estimates on improved demand from biotech clients for its tools used in drug developmen...
Waters Corporation (NYSE: WAT) Reports Third Quarter 2025 Financial Results
Highlights Sales of $800 million exceeded guidance; grew 8% as reported and 8% in constant currency Delivered GAAP EPS of $2.50 and non-GAAP EPS of $3.40, which reflects strong, 16% growth in Adjusted...